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ABSTRACT
Human bocavirus (HboV) is an emerging virus
that has been implicated as a cause of acute upper
and lower respiratory tract infection in children.
As no serological assay is available, PCR was
used to screen nasopharyngeal, serum or stool
samples from 16 patients with Kawasaki disease
for HBoV nucleic acid. HBoV was identiﬁed by
PCR in ﬁve (31.2%) patients, suggesting that this
emerging virus may also play a pathogenic role in
some cases of Kawasaki disease.
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Human bocavirus (HBoV) is a new member of
the Parvoviridae family that has recently been
described by Allander et al. [1]. Initial studies
revealed that this virus is a common cause of
acute upper and lower respiratory tract infection
in children, with a prevalence of 1.5–8.2% [2–7].
An initial study using nasopharyngeal aspirates
(NPAs) from children hospitalised with fever also
revealed HBoV nucleic acid in two patients
hospitalised with Kawasaki disease (KD). There-
fore, the present study retrospectively screened
NPA, serum or stool samples from patients with
KD for HBoV.
All NPA, serum and stool specimens were
collected in the 48-h period following admission.
NPAs had been tested previously for common
viral respiratory pathogens by direct immunoﬂu-
orescence assays using monoclonal antibodies for
respiratory syncytial virus, inﬂuenza A and B
viruses, parainﬂuenza virus types 1, 2, and 3, and
human adenovirus. NPAs were also inoculated
on HUH7 and A549 cell monolayers for virus
isolation. The specimens were then stored frozen
at either )80C (for NPAs) or )30C (serum and
stools) before being tested for the presence of
HBoV DNA.
DNAwas extracted from 200 lL of each sample
using a QIAamp DNA Blood Mini Kit (Qiagen,
Courtabeuf, France) according to the manu-
facturer’s instructions, with an elution volume
of 110 lL. DNA extracts of NPA were tested for
HBoV with a conventional in-house PCR assay.
Extracted DNA was stored at )80C between
performing the conventional PCR and a sub-
sequent real-time PCR assay.
The conventional in-house PCR targeted
the VP2 gene using forward primer 5¢-CAGTGG-
TACCAGACACCAGAAG and reverse primer
5¢-GCCAGTTCTTTGTTGCGTATCT. The corre-
sponding sequences are found in all the bocavirus
sequences deposited in GenBank. PCRs com-
prised 0.5 lL of 10 mM dNTP mix, 1.5 U of
AmpliTaq Gold DNA polymerase, 10 pmol of
each primer, 2 lL of 10· PCR buffer (100 mM
Tris-HCl, 500 mM KCl, 15 mM MgCl2, gelatin
0.01% w ⁄ v), 1 lL of glycerol and 2 lL of nucleic
acid extract in a ﬁnal volume of 20 lL. Ampliﬁ-
cation comprised 94C for 5 min, followed by 40
cycles of 94C for 15 s, 60C for 15 s and 72C for
30 s, and was performed using a GeneAmp PCR
System 9600 (Perkin Elmer, Warrington, UK). The
resulting 403-bp amplicon was detected using
conventional agarose gel electrophoresis. Ampli-
cons (403 bp) from each positive specimen were
sequenced in both directions to conﬁrm the
sequence speciﬁcity.
The real-time PCR assay targeted the HBoV
NS1 gene. Speciﬁc primers and probes were
based on the reported sequences of the NS1 gene
at positions 953–1029 of HBoV strain st1 (Gene-
Bank accession no. DQ000495), and are available
commercially as part of the Bocavirus r-gene kit
(Argene, Varilhes, France). The real-time PCR
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mixture comprised 15 lL of PCR Master premix
(Argene Bocavirus r-gene kit), 0.4 lL of Taq
polymerase and 10 lL of nucleic acid extract, in
a ﬁnal volume of 25 lL. Ampliﬁcation was
performed in 96-well plates on an ABI Prism 7000
Sequence Detection System (Applied Biosystems,
Warrington, UK). Ampliﬁcation comprised
10 min at 95C, followed by 45 cycles of 15 s at
95C and 60 s at 60C. Each run included a
positive and negative template control. To mon-
itor extraction quality, several extracts that tested
negative for HBoV were included in each
extraction batch and were tested by real-time
PCR with an assay for the human HAPB gene
(Applied Biosystems).
A specimen was only considered positive if the
PCRs were positive for both the VP2 and NS1
regions. Specimens that were positive according
to real-time PCR, but negative according to con-
ventional PCR for the VP2 gene, were
re-examined using a nested PCR for a different
region of the VP2 gene with two additional
pairs of primers (5¢-AGACAAAACGGAAGCA-
CAGC and 5¢-TCAAAGCCAGATCCAAATCC),
followed by sequencing to conﬁrm the speciﬁcity
of the amplicon.
Viral loads were measured in comparison with
a plasmid containing a 799-bp sub-genomic frag-
ment of HboV. This fragment was ampliﬁed from
NPA using primers bracketing the real-time PCR
target regions in the NS1 gene (forward primer
5¢-AAAAAACTACCACGCAACCCTAGA and
reverse primer 5¢-GAGAAACAGAATTGCCA-
CCAA). The product was cloned into plasmid
pGEM T easy (Promega, Charbonnieres, France).
Preparations of the puriﬁed plasmid were
sequenced for veriﬁcation and quantiﬁed by UV
spectroscopy (1012 copies ⁄mL). Measurement of
interferon-a in serum was performed using a
biological assay as described previously [8].
Nineteen children (mean age 4.8 years) were
hospitalised between January 1999 and December
2006 with typical symptoms of KD, meeting the
criteria of the American Heart Association [9], but
NPAs, sera and stools were available and tested
for only ten, 14 and eight patients, respectively (16
patients in all). A control population of 579
patients consisted of children aged <2 years who
were hospitalised for respiratory tract infections
between October 2005 and May 2006. HBoV was
detected in at least one sample from ﬁve (31.2%)
patients with KD. Clinical and microbiological
data for these ﬁve patients are summarised in
Table 1. In the control population, HBoV DNA
was detected in 32 (5.5%) patients. All ﬁve
patients with KD and HBoV infections were
hospitalised during the winter months, whereas
only eight of the 11 patients with KD who were
negative for HBoV were hospitalised during
winter.
All viral sequences isolated from the ﬁve
HBoV-positive patients showed 98% homology
with the reference sequence (GenBank
DQ000496). The viral load in four NPA samples
from KD patients had a median value of
6 · 103 genomic copies ⁄mL (range 102 to
6 · 104 copies ⁄mL). The median value of the viral
load in NPAs from 27 HBoV-positive non-KD
Table 1. Clinical and biological data for patients with Kawasaki disease from whom human bocavirus DNA was detected
Gender, age, month
of hospitalisation Clinical presentation
Coronary
aneurysms WBC ⁄mm3
CRP
(mg ⁄L)
PCT
(ng ⁄L)
Detection of HBoV
DNA by PCR
IFN-a
(IU ⁄mL) Co-infection
M, 8 years,
February
Fever, cervical adenopathy,
pharyngitis, conjunctivitis,
No 7900 3.3 0.2 Serum + 75 at day 6 Inﬂuenza B
in NPA at day 6
M, 12 months,
December
Fever, cervical adenopathy,
pharyngitis, exanthema
Aneurysm
of the left
coronary
artery
9000 327 20.1 NPA +
Serum –
<2
M, 21 months,
January
Fever, cervical adenopathy,
pharyngitis, conjunctivitis,
exanthema, oedema and
desquamation of the
extermities
No 5800 273 16.3 NPA +
Serum +
Stools +
2 at day 6 Rotavirus in stools
at day 6
M, 19 months,
February
Fever, cervical adenopathy,
pharyngitis, exanthema,
oedema of the
extremities
No 24 000 279 5.4 NPA +
Serum –
Stools –
<2
M, 21 months,
December
Fever, cervical adenopathy,
cheleitis, conjunctivitis,
exanthema
No 15 900 122 3 NPA +
Serum +
Stools –
CSF +
Serum <3
CSF <2
HBoV, human bocavirus; M, male; WBC, white blood cell; CRP, C-reactive protein; IFN, interferon; PCT, procalcitonin; NPA, nasopharyngeal aspirate; CSF, cerebrospinal
ﬂuid; IU, International Units.
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patients was 3 · 104 copies ⁄mL (range 3 · 10 to
1 · 1010 copies ⁄mL). In serum samples from KD
patients, the median viral load was 6 · 102
copies ⁄mL (range 10 to 4 · 104 copies ⁄mL),
compared with 3 · 10 to 1.2 · 105 copies ⁄mL in
HBoV-positive non-KD patients. In stools from a
KD patient, the viral load was estimated at
104 copies ⁄mL.
KD is an acute vasculitis affecting small to
medium-size vessels, leading to coronary aneu-
rysms in 20% of cases. The immunopathological
mechanisms involved in the pathogenesis of KD
are unclear. Although its aetiology remains
unknown, the clinical and epidemiological fea-
tures of this disease suggest that it is infectious
[10]. Epstein–Barr virus, adenovirus and cytomeg-
alovirus have all been considered as possible
agents that are involved in KD [11,12]. Members
of the genus Bocavirus, e.g., HboV, could also be
responsible for systemic infection, although
previous studies have only tested respiratory
samples. The present study detected HBoV in
three sera, one stool and one cerebrospinal ﬂuid,
which supports the hypothesis that this virus
could cause a systemic infection. HBoVmay play a
role in KD, and additional studies are required to
understand the physiopathology of this new virus.
ACKNOWLEDGEMENTS
C. Catalano-Pons and C. Giraud contributed equally to this
work.
REFERENCES
1. Allander T, Tammi MT, Erikson M et al. Cloning of a
human parvovirus by molecular screening of respiratory
tract samples. Proc Natl Acad Sci USA 2005; 102: 15712.
2. Sloots TP, McErlean P, Speicher DJ, Arden KE, Nissen MD,
Mackay IM. Evidence of human coronavirus HKU1 and
human bocavirus in Australian children. J Clin Virol 2006;
35: 99–102.
3. Arnold JC, Singh KK, Spector SA, Sawyer MH. Human
bocavirus: prevalence and clinical spectrum at a children’s
hospital. Clin Infect Dis 2006; 43: 283–288.
4. Bastien N, Brandt K, Dust K, Ward D, Li Y. Human
bocavirus infection, Canada. Emerg Infect Dis 2006; 12:
848–850.
5. Ma X, Endo R, Ishiguro N et al. Detection of human
bocavirus in Japanese children with lower respiratory tract
infections. J Clin Microbiol 2006; 44: 1132–1134.
6. Kesebir D, Vazquez M, Weibel C et al. Human bocavirus
infection in young children in the United States: molecular
epidemiological proﬁle and clinical characteristics of a
newly emerging respiratory virus. J Infect Dis 2006; 194:
1276–1282.
7. Manning A, Russell V, Eastick K et al. Epidemiological
proﬁle and clinical associations of human bocavirus and
other human parvoviruses. J Infect Dis 2006; 194: 1283–
1290.
8. Palmer P, Charley B, Rombaud B, Daeron M, Lebon P.
Antibody-dependent induction of type I interferon by
poliovirus in human mononuclear blood cell requires the
type II Fcg receptor (CD32). Virology 2000; 278: 86–94.
9. Taubert KA. AHA scientiﬁc statement. Diagnostic guide-
lines for Kawasaki disease. Circulation 2001; 103: 335–336.
10. Shulman ST, Rowley AH. Etiology and pathogenesis of
Kawasaki disease. Prog Pediatr Cardiol 1997; 6: 187–192.
11. Kikuta H, Sakiyama Y, Matsumoto S et al. Detection of
Epstein–Barr virus DNA in cardiac and aortic tissues from
chronic, active Epstein–Barr virus infection associated
with Kawasaki disease-like coronary artery aneurysms.
J Pediatr 1993; 123: 90–92.
12. Catalano-Pons C, Quartier P, Leruez-Ville M et al. Primary
cytomegalovirus infection, atypical Kawasaki disease, and
coronary aneurysms in 2 infants. Clin Infect Dis 2005; 41:
e53–e56.
1222 Clinical Microbiology and Infection, Volume 13 Number 12, December 2007
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 1199–1222
